K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 40.3 HKD -0.98% Market Closed
Market Cap: 11.3B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+52%
Revenue
Forecast
+73%
Operating Income
Forecast
+45%
Net Income
Forecast
+71%

Wall Street
Price Targets

Price Targets Summary
KeyMed Biosciences Inc

Wall Street analysts forecast KeyMed Biosciences Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 61.17 HKD with a low forecast of 55.55 HKD and a high forecast of 74.29 HKD.

Lowest Forecast
Wall Street Target
55.55 HKD
38% Upside
Average Forecast
Wall Street Target
61.17 HKD
52% Upside
Highest Forecast
Wall Street Target
74.29 HKD
84% Upside
Lowest
Price Target
55.55 HKD
38% Upside
Average
Price Target
61.17 HKD
52% Upside
Highest
Price Target
74.29 HKD
84% Upside
KeyMed Biosciences Inc Competitors:
Price Targets
EXAS
Exact Sciences Corp
24% Upside
IMNM
Immunome Inc
184% Upside
IMMX
Immix Biopharma Inc
259% Upside
PEB
Pacific Edge Ltd
19% Downside
EXAS
Exact Sciences Corp
24% Upside
IMNM
Immunome Inc
184% Upside
IMMX
Immix Biopharma Inc
259% Upside
PEB
Pacific Edge Ltd
19% Downside
300685
Amoy Diagnostics Co Ltd
53% Upside
LEGN
Legend Biotech Corp
171% Upside
MRNA
Moderna Inc
78% Upside
M
MAB
Mabion SA
18% Downside

Revenue
Forecast

Revenue Estimate
KeyMed Biosciences Inc

The compound annual growth rate of KeyMed Biosciences Inc's revenue for the next 3 years is 73%.

N/A
Past Growth
73%
Estimated Growth
Estimates Accuracy
13%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
KeyMed Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
27%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
KeyMed Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KeyMed Biosciences Inc's stock price target?
Price Target
61.17 HKD

According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 61.17 HKD with a low forecast of 55.55 HKD and a high forecast of 74.29 HKD.

What is KeyMed Biosciences Inc's Revenue forecast?
Projected CAGR
73%

The compound annual growth rate of KeyMed Biosciences Inc's revenue for the next 3 years is 73%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.